Marie-odile O. Petillon

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.

Journal: Haematologica

Published: June 14, 2024

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.

Journal: Haematologica

Published: October 14, 2022

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.

Journal: Leukemia

Published: May 18, 2021

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Journal: British journal of haematology

Published: March 21, 2019

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2018

Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Journal: Bulletin du cancer

Published: October 03, 2017

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 11, 2015

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Journal: American journal of hematology

Published: May 28, 2015

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Journal: Haematologica

Published: November 16, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026